Retrophin (RTRX) Upgraded to “Strong-Buy” at ValuEngine

Retrophin (NASDAQ:RTRX) was upgraded by analysts at ValuEngine from a “buy” rating to a “strong-buy” rating in a report issued on Wednesday.

A number of other equities analysts also recently commented on the stock. Jefferies Financial Group began coverage on shares of Retrophin in a research report on Tuesday, October 30th. They set a “buy” rating and a $44.00 price objective for the company. Zacks Investment Research upgraded shares of Retrophin from a “sell” rating to a “hold” rating in a research report on Thursday, September 27th. BidaskClub upgraded shares of Retrophin from a “hold” rating to a “buy” rating in a research report on Tuesday, August 28th. Finally, Canaccord Genuity began coverage on shares of Retrophin in a research report on Friday, August 17th. They set a “buy” rating for the company. One equities research analyst has rated the stock with a sell rating, four have assigned a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $43.50.

Shares of NASDAQ:RTRX opened at $27.05 on Wednesday. The firm has a market cap of $1.07 billion, a P/E ratio of -18.03 and a beta of 1.19. The company has a quick ratio of 4.99, a current ratio of 5.04 and a debt-to-equity ratio of 0.60. Retrophin has a 1-year low of $20.09 and a 1-year high of $33.00.

Retrophin (NASDAQ:RTRX) last announced its quarterly earnings data on Thursday, November 1st. The biopharmaceutical company reported ($0.92) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.53) by ($0.39). The firm had revenue of $40.70 million for the quarter, compared to analysts’ expectations of $44.36 million. Retrophin had a negative return on equity of 35.43% and a negative net margin of 69.38%. The firm’s quarterly revenue was up 1.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.15 EPS. As a group, research analysts expect that Retrophin will post -2.67 earnings per share for the current fiscal year.

In other Retrophin news, CEO Steve Aselage sold 12,000 shares of the company’s stock in a transaction on Friday, August 31st. The shares were sold at an average price of $32.00, for a total transaction of $384,000.00. Following the completion of the transaction, the chief executive officer now owns 257,883 shares in the company, valued at approximately $8,252,256. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 3.67% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently made changes to their positions in the business. BlackRock Inc. raised its position in Retrophin by 7.7% during the 2nd quarter. BlackRock Inc. now owns 3,512,643 shares of the biopharmaceutical company’s stock worth $95,754,000 after buying an additional 249,833 shares during the last quarter. Macquarie Group Ltd. increased its holdings in shares of Retrophin by 12.3% in the 2nd quarter. Macquarie Group Ltd. now owns 1,617,618 shares of the biopharmaceutical company’s stock valued at $44,096,000 after purchasing an additional 177,604 shares in the last quarter. Jennison Associates LLC increased its holdings in shares of Retrophin by 1.3% in the 2nd quarter. Jennison Associates LLC now owns 1,070,327 shares of the biopharmaceutical company’s stock valued at $29,177,000 after purchasing an additional 14,166 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Retrophin by 1.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 925,792 shares of the biopharmaceutical company’s stock valued at $20,701,000 after purchasing an additional 15,989 shares in the last quarter. Finally, Northern Trust Corp increased its holdings in shares of Retrophin by 6.3% in the 2nd quarter. Northern Trust Corp now owns 758,593 shares of the biopharmaceutical company’s stock valued at $20,679,000 after purchasing an additional 45,069 shares in the last quarter.

About Retrophin

Retrophin, Inc, a biopharmaceutical company, focuses on the development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria.

Further Reading: What does relative strength index mean?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply